Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: A meta-analysis

Leukemia and Lymphoma

Volumn 55, Issue 12, 2014, Pages 2691-2698

  Liu, Wen Jian ^a   Tan, Xiao Hong ^a   Luo, Xiu Ping ^a   Guo, Bao Ping ^a   Wei, Zhou Ji ^a   Ke, Qing ^a   He, Sha ^a   Cen, Hong ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia; Meta analysis; Mutation; Prognosis; TET2

Indexed keywords

DIOXYGENASE; HEMOGLOBIN; TET METHYLCYTOSINE DIOXYGENASE 2; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; ONCOPROTEIN; TET2 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; BIBLIOGRAPHIC DATABASE; CANCER CLASSIFICATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; EVENT FREE SURVIVAL; GENE MUTATION; GENOTYPE; HAZARD RATIO; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; META ANALYSIS; OVERALL SURVIVAL; QUALITY CONTROL; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; GENETICS; MORTALITY; MUTATION; PROGNOSIS; PUBLISHING;

ADULT; DNA-BINDING PROTEINS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PUBLICATION BIAS;

EID: 84919414970     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.893308     Document Type: Review

References (52)

1. Marcucci G, Haferlach T, Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011;29:475-486.
2. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075-4083.
3. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453-474.
4. Grimwade D, Hills RK, Moorman AV, et al. Ref nement of cytogenetic classif cation in acute myeloid leukemia: determination of prognostic signif cance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354-365.
5. Sabattini E, Bacci F, Sagramoso C, et al. WHO classif cation of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 2010; 102: 83-87.
6. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909-1918.
7. Shih AH, Abdel-Wahab O, Patel JP, et al. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012;12:599-612.
8. Grossmann V, Tiacci E, Holmes AB, et al. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood 2011;118:6153-6163.
9. Chou WC, Huang HH, Hou HA, et al. Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comblike 1 (ASXL1) mutations. Blood 2010;116:4086-4094.
10. Li M, Collins R, Jiao Y, et al. Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia. Blood 2011;118:5914-5917.
11. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic prof ling in acute myeloid leukemia. N Engl J Med 2012;366:1079-1089.
12. Zhou KG, Jiang LJ, Shang Z, et al. Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis. Leuk Lymphoma 2012; 53:2423-2429.
13. Shivarov V, Gueorguieva R, Stoimenov A, et al. DNMT3A mutation is a poor prognosis biomarker in AML: Results of a meta-analysis of 4500 AML patients. Leuk Res 2013; 37: 1445-1450.
14. Feng JH, Guo XP, Chen YY, et al. Prognostic signif cance of IDH1 mutations in acute myeloid leukemia: a meta-analysis. Am J Blood Res 2012;2:254-264.
15. Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011; 25: 1147-1152.
16. Li Z, Cai X, Cai CL, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011;118:4509-4518.
17. Yen K, Wang F, Schalm S, et al. Mutation selective IDH inhibitors mediate histone and DNA methylation changes. Blood 2012; 120 (Suppl. 1): Abstract 3509.
18. Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011; 478: 524-528.
19. Dawson MA, Prinjha RK, Dittmann A, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011;478:529-533.
20. Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009;41:838-842.
21. He YF, Li BZ, Li Z, et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011;333:1303-1307.
22. Saint-Martin C, Leroy G, Delhommeau F, et al. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood 2009;114:1628-1632.
23. Colaizzo D, Tiscia GL, Pisanelli D, et al. New TET2 gene mutations in patients with myeloproliferative neoplasms and splanchnic vein thrombosis. J T romb Haemost 2010; 8: 1142-1144.
24. Szpurka H, Jankowska AM, Makishima H, et al. Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations. Leuk Res 2010;34:969-973.
25. Rocquain J, Carbuccia N, Trouplin V, et al. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer 2010;10:401.
26. Ko M, Huang Y, Jankowska AM, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010;468:839-843.
27. Euba B, Vizmanos JL, Garcia-Granero M, et al. A meta-analysis of TET2 mutations shows a distinct distribution pattern in de novo acute myeloid leukemia and chronic myelomonocytic leukemia. Leuk Lymphoma 2012; 53: 1230-1233.
28. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360:2289-2301.
29. Weissmann S, Alpermann T, Grossmann V, et al. Landscape of TET2 mutations in acute myeloid leukemia. Leukemia 2012; 26: 934-942.
30. Gaidzik VI, Paschka P, Spath D, et al. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol 2012; 30: 1350-1357.
31. Wei JF, Chen GH, Qiu HY, et al. The incidence of TET2 gene mutation and its clinical signif cance in acute myeloid leukemia patients. Zhonghua Xue Ye Xue Za Zhi 2011; 32: 304-307.
32. Metzeler KH, Maharry K, Radmacher MD, et al. TET2 mutations improve the new European LeukemiaNet risk classif cation of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2011;29:1373-1381.
33. Kosmider O, Delabesse E, Mansat-De Mas V, et al. TET2 mutations in secondary acute myeloid leukemias: a French retrospective study. Haematologica 2011; 96: 1059-1063.
34. Chou WC, Chou SC, Liu CY, et al. TET2mutationisanunfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood 2011;118:3803-3810.
35. Nibourel O, Kosmider O, Cheok M, et al. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood 2010;116:1132-1135.
36. Abdel-Wahab O, Mullally A, Hedvat C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009;114:144-147.
37. Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from: http://www.ohri.ca/programs/clinical- epidemiology/oxford.asp
38. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-2834.
39. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
40. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
41. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820-826.
42. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
43. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.
44. Kosmider O, Gelsi-Boyer V, Cheok M, et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009;114:3285-3291.
45. Theferi A, Lim KH, Abdel-Wahab O, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009; 23: 1343-1345.
46. Theferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofbrosis. Leukemia 2009; 23: 905-911.
47. Mrozek K, Marcucci G, Paschka P, et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classifcation? Blood 2007;109:431-448.
48. Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005;106:3740-3746.
49. Becker H, Marcucci G, Maharry K, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene-and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 2010;28:596-604.
50. Marcucci G, Maharry K, Radmacher MD, et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol 2008;26:5078-5087.
51. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010;28:2348-2355.
52. Pollyea DA, Raval A, Kusler B, et al. Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors. Hematol Oncol 2011;29: 157-160.